Status:
UNKNOWN
Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University
Conditions:
PCSK9
Eligibility:
All Genders
Brief Summary
Rheumatoid arthritis (RA) has been proved to increase the incidence of atrial fibrillation (AF) with persistent systemic inflammation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been fo...
Detailed Description
Atrial fibrillation (AF), the most common clinically relevant arrhythmia, is an important contributor to population morbidity and mortality. Rheumatoid arthritis (RA) is a chronic systemic inflammator...
Eligibility Criteria
Inclusion
- Rheumatoid arthritis
- Rheumatoid arthritis combined with AF
Exclusion
- 1\. (1) History of hypertension, diabetes, cardiovascular disease, severe impairment of liver function, severe renal insufficiency.
- (2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases.
- 2\. (1) History of hypertension, diabetes, cardiovascular disease (except for AF), severe impairment of liver function, severe renal insufficiency.
- (2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases.
Key Trial Info
Start Date :
November 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2022
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05191342
Start Date
November 1 2021
End Date
November 1 2022
Last Update
January 13 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
the first affiliated hospital of Harbin medical university
Harbin, Heilongjiang, China, 150001
2
Thrombelastogram
Harbin, Heilongjiang, China, 150001